

[54] **COMPOSITION AND METHOD FOR TRANSPLANTATION THERAPY**

[75] **Inventor:** Lynn E. Spitler, Tiburon, Calif.

[73] **Assignee:** Xoma Corporation, San Francisco, Calif.

[21] **Appl. No.:** 434,782

[22] **Filed:** Oct. 18, 1982

Related U.S. Application Data

[62] Division of Ser. No. 276,579, Jun. 23, 1981, abandoned.

[51] **Int. Cl.³** C07G 17/00; C07G 7/00; C07G 11/00; A61K 39/00

[52] **U.S. Cl.** 128/1 R; 424/85

[58] **Field of Search** 424/85; 128/1 R; 435/1

[56] **References Cited**

FOREIGN PATENT DOCUMENTS

2038836 7/1980 United Kingdom 424/85

OTHER PUBLICATIONS

W. Müller—Ruchholtz, et al., Transplantation Proceedings, vol. VIII pp. 537-541, 12/1976.

Reinherz, et al., The Journal of Immunology, vol. 123, No. 3, pp. 1312-1317, 9/1979.

Reisner, et al., Proc. Natl. Acad. Sci., vol. 77, No. 2, pp. 1164-1168, 2/1980.

Youle, et al., Proc. Natl. Acad. Sci., vol. 77, No. 9, pp. 5483-5486, 9/1980.

Raso, et al., J. of Immunology, vol. 125, pp. 2610-2616, 12/1980.

Primary Examiner—Richard J. Apley

Assistant Examiner—Greg Beaucage

Attorney, Agent, or Firm—Townsend & Townsend

[57] **ABSTRACT**

An improved transplantation therapy and method is provided which comprises specifically killing cells known to be problematic in the transplantation process. Novel compositions of the present invention are conjugates prepared by generating antibodies specific to surface receptors of the unwanted cells, preparing Fab or F(ab')₂ fragments from the antibodies, and coupling the fragments to A chains of lectins or other cytotoxic agents to render the conjugates thus formed strongly cytotoxic to the cells to which the antibody was directed. The conjugates are used in vitro to eliminate unwanted cells prior to bone marrow transplantation.

6 Claims, No Drawings